Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Catequentinib · AL-3818

Small molecule · Inhibitor of vascular endothelial growth factor receptor 2 (KDR) and vascular endothelial growth factor receptor 3 (FLT4) · developed by Chia Tai Tianqing Pharmaceutical Group Co.

Phase 2 Most advanced trial
2 Registered trials

What is Catequentinib?

Catequentinib (also known as anlotinib) is an oral receptor tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases, including VEGFR2 and VEGFR3, to inhibit angiogenesis and tumor cell growth. It is being studied in non-small cell lung cancer and platinum-resistant recurrent clear cell ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AL-3818, Anlotinib
Drug type
Small molecule
Targets
vascular endothelial growth factor receptor 2 (KDR), vascular endothelial growth factor receptor 3 (FLT4)
Mechanism
Inhibitor of vascular endothelial growth factor receptor 2 (KDR) and vascular endothelial growth factor receptor 3 (FLT4)
Pathways
angiogenesis, tumor cell growth
Therapy area
Oncology
Developer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
In trials of
ONC, ZLAB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
GKF8S4C432

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07885709 Phase 2 Non-Small Cell Lung Cancer (NSCLC) Not yet recruiting ONC
NCT05130515 Phase 2 Platinum-resistant Recurrent Clear Cell Ovarian Cancer Completed ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Small Cell Lung Cancer (NSCLC)Platinum-resistant Recurrent Clear Cell Ovarian Cancer

Other drugs acting on KDR / FLT4

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.